Where Adient Stands With Analysts
Analysts have provided the following ratings for Adient (NYSE:ADNT) within the last quarter:
Looking Into Adient’s Return On Invested Capital
Benzinga Pro data, Adient (NYSE:ADNT) reported Q2 sales of $3.51 billion. Earnings fell to a loss of $60.00 million, resulting in a 100.0% decrease from last quarter.
Expert Ratings for Adient
Over the past 3 months, 5 analysts have published their opinion on Adient (NYSE:ADNT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Barclays Maintains Equal-Weight on Adient, Lowers Price Target to $37
Barclays maintains Adient (NYSE:ADNT) with a Equal-Weight and lowers the price target from $45 to $37.
Wells Fargo Maintains Overweight on Adient, Lowers Price Target to $50
Wells Fargo analyst Colin Langan maintains Adient (NYSE:ADNT) with a Overweight and lowers the price target from $60 to $50.
